David Meek was appointed CEO of Ipsen in July 2016. He is also on the Board of Directors of Ipsen. David has over 25 years of experience in the pharmaceutical industry where he has held various global executive positions in major pharmaceutical and biotechnology companies. Prior to joining Ipsen David was Executive Vice-President and President of the oncology division of Baxalta. David started his biopharma career at Johnson & Johnson and Janssen Pharmaceutica (1989-2004) where he held a variety of senior US sales and marketing positions across therapeutic areas in primary care, specialty care, and oncology. He then joined Novartis (2005-2012), where he successively served as the global business franchise head for the company’s respiratory and dermatology franchise in Basel, Switzerland; President and Chief Executive Officer of the pharmaceutical division in Canada; and the head of oncology for Northern, Central and Eastern Europe. From 2012 to 2014, he served as Chief Commercial Officer of Endocyte, an oncology biotechnology company. Prior to his biopharma career David was an officer in the United States Army. He is a graduate of the University of Cincinnati.